After many years of research and development, ATANIS Biotech AG was incorporated as a spinoff of the University of Bern in June 2021. The four co-founders Noemi Zbären, Jean-Pierre Kinet, Thomas Kaufmann and Alexander Eggel bring >70 years of combined experience in basic and clinical allergy research, cell and molecular biology and diagnostic assay development to the company and have published >250 publications in peer-reviewed high-impact journals.
Our team
Prof. Dr. Jean-Pierre Kinet
Co-Founder & CEO
Mrs. Noemi Bachmeier-Zbären
Co-founder & CTO
Mr. Nathan Laborde
Quality Assurance Manager
Mrs. Charlène Niogret
Clinical Affairs Manager
Mrs. Antonia Ferreira
Research Assistant
Mrs. Robin van Brummelen
Research Assistant
Mrs. Marianne Zwicker
Laboratory Manager
Mrs. Sophie Buchser
Research Assistant
Prof. Dr. Thomas Kaufmann
Co-Founder & Scientific Advisor
Prof. Dr. Alexander Eggel
Co-Founder & Scientific Advisor
Our Customers
Our customer base reaches from highly established industrial partners to individual research groups.
IgGenix
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade.
Mabylon
Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies and neurodegenerative diseases.
CSL Behring
CSL Behring is a leading global biotech company driven by its promise to save and improve lives.
Excellergy
Excellergy is a biotechnology company developing new therapeutic modalities in various diseases.
KGK Science
KGK Science provides high-quality clinical research trials and expert regulatory support for the nutraceutical industries.
Octapharma AG
Octapharma is one of the largest human protein product manufacturers.
Our Investors
Are you interested to invest in ATANIS Biotech AG or to financially support us? Please get in touch!
